What Is Xenetic Biosciences, Inc. (XBIO) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, our multi-model framework produces a cautiously optimistic read on Xenetic Biosciences, Inc. at $3.00. With an estimated intrinsic value of $5.03 and 8 of 11 models pointing higher, the average implied return is +67.5%. The most optimistic model, Dynamic NAV, places fair value at $11.52 (+283.9%), while ML-RIV — the most conservative — estimates $0.95 (-68.2%). This +352.1% gap reflects genuine analytical uncertainty about Xenetic Biosciences, Inc.'s intrinsic worth.
What Do the Models Say About XBIO?
11 of 13 models are currently active for XBIO. Of these, 8 models suggest upside while 3 models suggest overvaluation. The Bayesian DCF estimates XBIO's intrinsic value at $2.52, implying -15.9% downside from the current price. See which stocks rank higher →
How Does XBIO Rank in Pharmaceutical Preparations?
Among 469 Pharmaceutical Preparations stocks, XBIO ranks #79 by Quality of Company score. CirclFi's QOC score of 6.7/10 evaluates 32 fundamental signals. A score of 6.7 indicates above-average quality.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Xenetic Biosciences, Inc.'s positioning within the Pharmaceutical Preparations segment means that revenue per drug plays an outsized role in fundamental analysis. The sector's unique characteristics — including therapeutic area leadership — shape both the opportunity set and risk profile.
Is XBIO a Value Trap?
CirclFi's Value Trap algorithm assigns XBIO a score of 12/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
11 of 13 models are active for Xenetic Biosciences, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, Xenetic Biosciences, Inc. earns a quality score of 6.7/10. This respectable rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.
The gap between the most bullish and bearish model spans +352.1% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every XBIO valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across XBIO's 11 active models, average confidence is 21%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad